AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler

27-01-2022

Muireann Bolger

AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler

Tada Images / Shutterstock.com

AstraZeneca has urged the US Court of Appeals for the Federal Circuit to revisit a split panel decision that breathed new life into Mylan’s bid to produce a generic version of the asthma inhaler, Symbicort Turbohaler.


AstraZeneca, US Court of Appeals for the Federal Circuit, split panel decision, Mylan, generic, asthma inhaler, Symbicort Turbohaler, Kindeva

LSIPR